Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5204304
Max Phase: Preclinical
Molecular Formula: C34H41N5O6
Molecular Weight: 615.73
Associated Items:
ID: ALA5204304
Max Phase: Preclinical
Molecular Formula: C34H41N5O6
Molecular Weight: 615.73
Associated Items:
Canonical SMILES: C[C@@H](O)C(=O)CCCCC[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](n2ccc3ccccc32)NC1=O
Standard InChI: InChI=1S/C34H41N5O6/c1-22(40)29(41)17-7-3-6-14-25-31(42)37-30(38-20-18-24-13-8-9-15-27(24)38)33(44)36-26(21-23-11-4-2-5-12-23)34(45)39-19-10-16-28(39)32(43)35-25/h2,4-5,8-9,11-13,15,18,20,22,25-26,28,30,40H,3,6-7,10,14,16-17,19,21H2,1H3,(H,35,43)(H,36,44)(H,37,42)/t22-,25+,26+,28-,30+/m1/s1
Standard InChI Key: ZTOPZCOUZQXWSK-RLQIRPRCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 615.73 | Molecular Weight (Monoisotopic): 615.3057 | AlogP: 2.37 | #Rotatable Bonds: 10 |
Polar Surface Area: 149.84 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.34 | CX Basic pKa: | CX LogP: 2.80 | CX LogD: 2.80 |
Aromatic Rings: 3 | Heavy Atoms: 45 | QED Weighted: 0.26 | Np Likeness Score: 0.47 |
1. Qiu X, Zhu L, Wang H, Tan Y, Yang Z, Yang L, Wan L.. (2021) From natural products to HDAC inhibitors: An overview of drug discovery and design strategy., 52 [PMID:34826681] [10.1016/j.bmc.2021.116510] |
Source(1):